Navigation Links
Anavex comments on failure of Pfizer and Medivation's Alzheimer's investigational drug Dimebon during Phase 3 clinical trials
Date:3/3/2010

ANAVEX's SIGMACEPTOR(TM)-N program involves the development of novel and original drug candidates that target neurological and neurodegenerative diseases (Alzheimer's disease, epilepsy, depression, pain). The company's lead drug candidates exhibit high, non-exclusive affinity for sigma receptors, which have been extensively documented as potentially valuable drug targets and have demonstrated evidence for anti-amnesic and neuroprotective properties. The company is developing non-amyloid focused approaches to disease modification in Alzheimer's disease. ANAVEX 1-41 and ANAVEX 2-73 modulate sigma receptors, a unique class of receptor molecules, to guard against oxidative stress and work through alternative mitochondrial pathways via ion channel signalling. So far the compounds have performed extremely well in well-recognized animal models of Alzheimer's disease, underscoring the promise of the company's new alternative approach to the disease.

ANAVEX's SIGMACEPTOR(TM)-C program involves the development of novel and original drug candidates targeting cancer. The company's lead drug candidates exhibit high, non-exclusive affinity for sigma receptors with strong evidence for selective pro-apoptotic, anti-metastatic and low toxicity properties in various types of solid cancers. ANAVEX 7-1037 has already demonstrated its ability to significantly delay the growth of cancerous tumors in patient-derived xenografts during advanced pre-clinical studies.


'/>"/>
SOURCE Anavex Life Sciences Corp.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Anavex appoints Dr. Dimitri Goundis to lead Clinical Development
2. Anavex 7-1037 reduces rate of cancer tumor growth 69% in pre-clinical studies, compared to currently marketed drug Dacarbazine showing no measurable activity
3. Anavex strengthens Board of Directors
4. Anavex advances drug candidate for treatment of Alzheimers disease
5. American Medical Informatics Association (AMIA) Submits Comments to Hit Policy Committee About Meaningful Use and Electronic Health Record Certification
6. Amylin Comments on RiskMetrics Report
7. The Society of Forensic Toxicologists Comments on the National Academy of Sciences Report on Strengthening Forensic Science in the United States
8. American Oriental Bioengineering Comments on Recent Property Purchase
9. Boston Scientific Provides Comments Reinforcing Strength of Its Balance Sheet
10. Dietitian Mary Lee Chin Comments on Proven Value and Safety of Food Biotechnology in New Online Video
11. KV Pharmaceutical Company Comments on Legal Development in Its Branded Pharmaceutical Business
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/18/2014)... Aug. 18, 2014 /PRNewswire/ - SQI Diagnostics Inc. (TSX-V: SQD), ... technologies and products for advanced microarray diagnostics, today announced ... August 22 at 2:00 pm ET.  ... provide a brief review of SQI,s recent commercialization progress ... diagnostics industry veteran recently appointed to the Board of ...
(Date:8/18/2014)... 18, 2014   Sterne, Kessler, Goldstein & Fox ... Washington, DC , announced today that it ... (IPR) with the U.S. Patent and Trademark Office ... BioReference Laboratories, Inc. (Nasdaq: BRLI).  These IPR petitions aim ... Myriad Genetics, Inc. These patents have been asserted against ...
(Date:8/18/2014)... HIV Infection Drug Market and Pipeline Insight is a ... infection and the number of deaths due to AIDS has ... the globe. It has been estimated that the death rate ... with the rates for children being even much lower. A ... has been the improved access to antiretroviral drugs and therapy ...
(Date:8/18/2014)... 18, 2014 According to ... By Application (Municipal Wastewater Treatment and Industrial Wastewater ... Multi Tubular), By Configuration (Internal/Submerged and External/Sidestream), and ... MarketsandMarkets, The market for membrane bioreactor systems is ... at a CAGR of 15.28% between 2014 and ...
Breaking Biology Technology:SQI Diagnostics Announces Investor Conference Call with Dr. Allan Pronovost 2SQI Diagnostics Announces Investor Conference Call with Dr. Allan Pronovost 3Sterne Kessler Files 11 IPR Petitions On Behalf Of GeneDx, Inc., Subsidiary Of BioReference Laboratories, Inc. 2Sterne Kessler Files 11 IPR Petitions On Behalf Of GeneDx, Inc., Subsidiary Of BioReference Laboratories, Inc. 3Global HIV Infection Drug Market Overview 2Global HIV Infection Drug Market Overview 3Global HIV Infection Drug Market Overview 4Membrane Bioreactor Systems Market Worth $2,927 Million by 2019 2Membrane Bioreactor Systems Market Worth $2,927 Million by 2019 3
... Since the cloning of Dolly the Sheep ... been considered a promising way to generate human, patient-specific stem ... has led to efforts to substitute animal oocytes. However, a ... 11, Number 2, 2009 issue of Cloning and Stem ...
... To highlight its 20 years of experience as ... ( www.microtestlabs.com ) is offering free microbial identification ... tests, to eligible attendees visiting the Microtest exhibit, #828, ... highlight Microtest,s wide range of laboratory testing and validation ...
... RGEN ) announced today that the Company ... will present at the BIO CEO and Investor Conference ... at the Waldorf-Astoria Hotel, 301 Park Avenue, New York, ... available via Repligen,s website at www.repligen.com and ...
Cached Biology Technology:Animal Eggs Not Suitable Substitutes to Produce Stem Cells 2Animal Eggs Not Suitable Substitutes to Produce Stem Cells 3Microtest Labs Offers Free Microbial Identification Testing, Free Shipping on Other Tests, to MD&M West Attendees 2Repligen to Present at the BIO CEO & Investor Conference Monday, February 9th, 11:30 a.m. EST 2
(Date:8/19/2014)... in supermarkets to encourage healthier spending habits? A new ... very question by tracking the purchasing records in a ... rate the nutritional value of foods for sale. , ... Just, PhD, and Brian Wansink PhD, author of Slim ... 150 Hannaford Supermarkets in the Northeastern United States between ...
(Date:8/19/2014)... Long-Term Ecological Research and Network-Level Science, , Imagine if ... range of ecosystems was responding to global changes in ... if it coupled multiple decades of information about ecological ... models from dozens of different ecosystem types. , ... Ecological Research (LTER) Network, which will soon celebrate its ...
(Date:8/19/2014)... In many parts of the world, leprosy and ... new cases of leprosy per year, with nearly ... The currently available century-old vaccine Bacille Calmette-Guerin, or ... and leprosy, so a more potent vaccine is ... have found a stronger weapon against both diseases., ...
Breaking Biology News(10 mins):This week from AGU: Long-term ecological research, predicting cholera outbreaks 2New vaccine shows promise as stronger weapon against both tuberculosis and leprosy 2
... Community support of school obesity prevention programs is ... children, according to researchers at the Michael & Susan ... part of The University of Texas Health Science Center ... behavioral sciences at UTHealth,s School of Public Health Austin ...
... chemistry professor David Cramb is a step closer to ... nanoparticles have on human health and the environment. ... and his researchers have developed a methodology to measure ... chicken embryos. Their discovery is published in the March ...
... CA Researchers at Charles Drew University of Medicine ... health of low-birth-weight babies and their parents as part ... associated with low-weight births. Karen Cheng, CDU ... informatics professor, were awarded a $480,000 grant from the ...
Cached Biology News:Community involvement important in fight against childhood obesity, according to UTHealth researchers 2Vigilance needed in nanotechnology 2Charles Drew University, UC Irvine awarded $480,000 grant for research low birth weight infants 2Charles Drew University, UC Irvine awarded $480,000 grant for research low birth weight infants 3
Human Legumain Affinity Purified Polyclonal Ab...
Human Cystatin F MAb (Clone 292103)...
... Ac-DEVD-CHO is an ... activity. The concentration of ... caspase activity must be ... system. Ten micromolar inhibitor ...
Human RELT/TNFRSF19L Affinity Purified Polyclonal Ab...
Biology Products: